U bent hier: Home > Therapeutics (voormalig) > Future of Cannabis and Cannabinoids in Therapeutics

J Cannabis Ther 2003(3/4):163-174

Review and Outlook

Future of Cannabis and Cannabinoids in Therapeutics

Author
E. Russo

Abstract
This study reviews human clinical experience to date with several synthetic cannabinoids, including nabilone, levonantradol, ajulemic acid (CT3), dexanabinol (HU-211), HU-308, and SR141716 (Rimonabant®). Additionally, the concept of "clinical endogenous cannabinoid deficiency" is explored as a possible factor in migraine, idiopathic bowel disease, fibromyalgia and other clinical pain states. The concept of analgesic synergy of cannabinoids and opioids is addressed. A cannabinoid-mediated improvement in night vision at the retinal level is discussed, as well as its potential application to treatment of retinitis pigmentosa and other conditions. Additionally noted is the role of cannabinoid treatment in neuroprotection and its application to closed head injury, cerebrovascular accidents, and CNS degenerative diseases including Alzheimer, Huntington, Parkinson diseases and ALS. Excellent clinical results employing cannabis based medicine extracts (CBME) in spasticity and spasms of MS suggests extension of such treatment to other spasmodic and dystonic conditions. Finally, controversial areas of cannabinoid treatment in obstetrics, gynecology and pediatrics are addressed along with a rationale for such interventions.


Keywords
Nabilone, levonantradol, ajulemic acid, dexanabinol, HU-308, SR141716, cannabis, medical marijuana, migraine, idiopathic bowel disease, fibromyalgia, night vision, retinitis pigmentosa, neuroprotection, dystonia, obstetrics, gynecology, pediatrics

PDF van de volledige tekst ]

Online evenementen 2020

Alle informatie over de IACM Online Events, inclusief gratis video's van de webinars met Nederlandse ondertitels, vindt u hier.

Conferentie 2021

 De 12e IACM-conferentie over Cannabinoïden in de Geneeskunde zal online worden gehouden van 14 tot 16 oktober 2021. Registratie is gratis.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.